Zhang, Qi

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Du, J., Fu, W.-J., Jiang, H., Dong, B., Gao, L., Liu, L., Ge, J., He, A., Li, L., Lu, J., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 35

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Du, J., Qiang, W., Lu, J., Jia, Y., He, H., Liu, J., Guo, P., Yang, Y., Feng, Z., Jin, L., et al. (2023) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 21